minor issues in CRL it's only about the "PEZ dispenser" and failsafe engineering of cartridge depenser..... HZNP has had its drugs excluded from the forularies of CVS Caremark (30% of their sales)
this is one weird stock ..... had a hard-on for 11.50 and now at the whim of the S&P ticking up and down a few cents in harmony with SPY, crazy low volume now like a weather vane in light shifty inconsequential summer breezes
definitely a day trading instrument. I don't know which way this is careening next but i do believe it's upside is limited if the market as a whole continues to retrace
red ink as far as the eye can see....soon to become a feckless patent troll, but short interest is @30% of the float and is fast money easily squeezed
never cut with a dull knife, or don't catch one, the soul of brevity is a well aimed bodkin
well, if they aren't getting some of their compensation in shares, they are going to miss out big time. this sector of biotech is going to heat up ...way up:
FRANKFURT/LONDON, June 23 (Reuters) - Bayer has struck an alliance with U.S. biotech firm Dimension Therapeutics to develop a gene therapy for the treatment of haemophilia A, marking renewed interest in an approach to tackle the cause of diseases at a cellular level.
Gene therapy involves inserting corrective genes into malfunctioning cells to get them to work again without further use of drugs. Dimension has been looking into using viruses to carry the genes to the affected cells.
Gene therapy has seen more than 20 years of experiments and a series of disappointments. However, Amsterdam-based UniQure is about to start selling its gene therapy drug Glybera in Europe as a treatment for the ultra-rare disease lipoprotein lipase deficiency (LPLD) with partner Chiesi.
it will be bought out, but not likely before 1st quarter next yr. big boyz love to feel the power they have to deny the future challenge to their current biz models and profit margins (power loves to be a moron)....looking for a market pull-back (like every other idiot on the block) to pick up a sizable chunk of my mid-term portfo. in AUDC sometime before end of yr.
Interesting that the first gen treatment worked as well. They are onto something big here. If they could do an IPO based largely on that, the most recent results are even more significant than previously thought; and, if sickle cell is in the sights of this treatment, the sky in the limit for the stock.
very low float, a lot of it is shorted, a lot of it is underwater. So at @ $40 it is a battle to force short covering while ideally forestalling underwater holders from selling into their covering to make it easy on the shorts.
So, hold if you bought this for the long-term story. The float is small enough you may not get a chance to own it this cheap, especially now that retail directed stock commentators like The Street are on the case.
i am confident they have figured out how to conduct precisely targeted gene therapy for certain disease causing genes. a remarkable one-time fix. if so, the stock ought to be a bit of a rocket, just based on the platform and its wide potential applications
15 new patients are going to undergo the treatment that has saved the lives of the two who so far have done so. if those 15 have anything like a similar outcome. this is going north of $100 to open as gene therapy, if consistently successful, will be a tremendous breakthrough as a platform for treatment of many many diseases.
it is odd that the writer observes a bidding war for IDIX but no interest in ACHN from the losers is even considered. One wonders if the man could pass and elementary course of logc
this one could run into the close and into tomorrow, at least up to resistance @$2.20. fairly low float here so if shorts get aggressive, a squeeze is a strong possibilty
lol...this market is relentless in the up direction so long as the FED and Drahgi keep talking about pumping liquidity into the world economy, and now the Chinese are talking stimulus ... in this environment, this sleeping giant might be comatose to brain dead for some time. got to watch the freaking thing though. if the algorithms ever stop buying each tiny dip in the market, comatose, if not brain dead TVIX may be worth a rethink. It's a Vampire sucking every long down deeper into Hell unless and until the darker angels infuse the world with new fear, and free the Vampire with renewed appetite.
i will gladly pay you a penny tomorrow for a share of NEWL today! (apologies to J Wellington Wimpy)
martha sez $.165 cents will be the equivalent of the @ $.40 cents it reached when the float was 10.4 million ( thanks to the additional shares issued to Hanover over the weekend) the NEWL float is now 25.4 million...